Trial
NCT01453140
In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Hackensack Meridian Health
Collaborators
—
Condition
Graft Versus Host Disease
Intervention
Cyclophosphamide and Sirolimus
Why stopped
Dose Limiting Toxicities
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-08